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Asthma is characterized by chronic inflammation 
of the airways, contraction of smooth muscle, 
overproduction of mucus, and remodeling of the 
airway wall. In many forms of asthma, there is an 
accumulation of eosinophils, which predicts a 
good response to inhaled glucocorticoids. Eosino-
philic inflammation is controlled by type 2 help-
er T (Th2) lymphocytes of the adaptive immune 
system, which make interleukin-4, interleukin-5, 
and interleukin-13 in response to the presentation 
of an allergen by dendritic cells in the airway. 
However, many features of asthma can also be 
controlled by type 2 innate lymphoid cells, which 
cannot specifically recognize allergens but do 
produce interleukin-5 and interleukin-13 when 
stimulated by cytokines made by lung epithelial 
cells and macrophages.
Although immune cells control all the fea-
tures of asthma, it is unclear why and how they 
react to allergens. Most organisms that express 
allergens, such as pollinating plants, house-dust 
mites, cockroaches, and environmental fungi, 
are not intrinsically pathogenic to the host. How-
ever, some proteins or lipids of these organisms 
trigger pattern-recognition receptors of the mam-
malian immune system. For example, the house-
dust mite is known to carry at least 20 allergens 
that can induce IgE responses in humans. In 
mice, the development of an asthmalike condi-
tion triggered by house-dust mites depends on the 
expression of toll-like receptor 4 (TLR4) on airway 
epithelial cells.1 Although many allergens contain 
lipopolysaccharide, which can potentially bind 
and activate TLR4, it is also possible that TLR4 
is triggered by endogenous danger signals that 
are released on exposure to allergens.
Some allergens have proteolytic activity and 
trigger protease-activated receptors on barrier epi-
thelial cells and dendritic cells, but until the re-
cent publication of an article by Millien et al.,2 
there was no known link between protease al-
lergens and TLR4 signaling. Millien et al. found 
that TLR4 has a critical role in the allergic re-
sponse to fungal proteases, such as those derived 
from environmental aspergillus species.
Colonization by aspergillus is frequently found 
in patients with severe asthma, and it causes 
allergic bronchopulmonary aspergillosis, a syn-
drome characterized by eosinophilic pulmonary 
infiltrates, high production of IgE, and central 
bronchiectasis. Millien and colleagues found that 
the development of airway inflammation, mucus 
hypersecretion, and bronchial hyperreactivity in 
response to the inhalation of an aspergillus pro-
tease depends on TLR4 and its downstream 
adaptor molecules (Fig. 1). As compared with 
wild-type control mice, TLR4-deficient mice, on 
exposure to aspergillus protease, showed a paltry 
recruitment of type 2 innate lymphoid cells (de-
spite normal numbers of Th2 cells) and a reduc-
tion in asthmalike features.
Millien et al. also found that the activation of 
TLR4 in wild-type mice by a fungal protease was 
indirect and required the presence of a serum 
factor. While trying to identify the responsible 
Figure 1 (facing page). Fibrinogen Cleavage Products 
in Asthma.
When fungal spores or proteases from aspergillus are 
inhaled, they can trigger the activation of dendritic cells 
that cause the development of type 2 helper T (Th2) 
immunity in the draining lymph nodes. Th2 lympho-
cytes then return to the lungs to cause mild eosino-
philia and mucus production by goblet cells. Millien 
and colleagues2 found that fungal proteases subse-
quently cleave fibrinogen into fibrin and fibrinogen 
cleavage products (FCPs). The FCPs trigger the toll-like 
receptor 4 (TLR4) on epithelial cells to cause the recruit-
ment of type 2 innate lymphoid cells (ILC2s), which 
further boost airway eosinophilia and mucus produc-
tion. The fibrin assembles with mucus to form plugs 
that can obstruct the airways. At the same time, TLR4 
triggering by FCPs causes macrophages to inhibit fun-
gal growth. This system in which a molecule involved 
in coagulation activates TLR4 is reminiscent of the way 
Toll is activated by Spätzle in fruit flies.
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serum component, the authors considered how 
toll-like receptors were discovered in the model 
organism drosophila. Mutations in the genes Toll 
and Spätzle caused fruit flies to be colonized by 
Aspergillus fumigatus.3 The Toll ligand pro-Spätzle 
is activated by a serine protease — a mechanism 
that also underlies the activation of coagulogen, 
a clotting factor of the horseshoe crab, an inver-
tebrate that has changed little over the past 400 
million years.4 Millien et al. found that, similarly, 
fungal proteases cleave the serum factor fibrin-
ogen, thus causing clot formation and releasing 
fibrinogen cleavage products that can activate 
TLR4. The activation of TLR4 by fibrinogen cleav-
age products subsequently triggers antifungal 
immunity and fungistasis of aspergillus conidia 
grown on alveolar macrophages, just as it does 
in drosophila.
Thrombin, the classic activator of coagulation, 
also generates fibrinogen cleavage products from 
fibrinogen, thus triggering TLR4. The thrombin 
inhibitor hirudin was able to suppress aspergil-
lus-driven asthmalike changes in mice, but it 
also suppressed asthmalike changes driven by 
the model antigen ovalbumin, which has no pro-
tease activity.2 Allergen challenge in humans and 
mice is generally accompanied by the extravasa-
tion of plasma, platelet aggregation, and activa-
tion of the coagulation cascade in the lung inter-
stitium and bronchoalveolar compartment, with 
elevations of tissue factor, thrombin, and fibrin-
ogen, which explains how fibrinogen cleavage 
products can be generated with most allergens.5
Millien et al. found that activation of the co-
agulation cascade by endogenous or allergen-
derived proteases is an important factor in driv-
ing asthmalike changes in mice by means of 
TLR4 signaling. Additional research is required 
to evaluate whether this finding can be trans-
lated into clinical applications. The fibrinogen 
cleavage products need to be defined more pre-
cisely before drug candidates can be screened. It 
remains to be determined whether fibrinogen 
cleavage products are present in the affected air-
ways of persons with asthma. Although Millien 
et al. were able to suppress aspergillus-induced 
asthmalike changes by blocking the generation 
of fibrinogen cleavage products, it is notable that 
trials of inhaled (low-molecular-weight) heparin 
in the context of allergen-challenge studies in-
volving humans have yielded various effects. 
Given the heterogeneous nature of the disease, 
it is conceivable that a subset of patients with 
asthma may one day benefit from antithrombotic 
medications.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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